Vanguard Group Inc Galectin Therapeutics Inc Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,134,205 shares of GALT stock, worth $6.15 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,134,205
Previous 2,116,072
0.86%
Holding current value
$6.15 Million
Previous $4.78 Million
22.73%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding GALT
# of Institutions
91Shares Held
9.65MCall Options Held
1.16MPut Options Held
1.98M-
Black Rock Inc. New York, NY1.56MShares$4.5 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$3.4 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$2.48 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.39 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$1.15 Million0.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $171M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...